LEADER 04451nam  22006615  450 
001 9910298399603321
005 20200703143247.0
010   $a3-319-74186-1
024 7 $a10.1007/978-3-319-74186-4
035   $a(CKB)4100000005958212
035   $a(MiAaPQ)EBC5497918
035   $a(DE-He213)978-3-319-74186-4
035   $a(PPN)229918425
035   $a(EXLCZ)994100000005958212
100   $a20180823d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug Resistance in Leishmania Parasites $eConsequences, Molecular Mechanisms and Possible Treatments /$fedited by Alicia Ponte-Sucre, Maritza Padrón-Nieves
205   $a2nd ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (380 pages)
311   $a3-319-74185-3 
327   $aPrologue -- Introduction -- Part I Determinant features in Leishmaniasis -- Molecular evolution and phylogeny of Leishmania -- The role of reservoirs: canine Leishmaniasis -- Epidemiology of Leishmaniasis in the time of drug resistance -- The role of the immune system in resistance to infection -- Part II Challenges in the diagnosis, treatment and control of Leishmaniasis in the times of drug resistance -- Co-infection with HIV -- Visceral Leishmaniasis -- Tegumentary Leishmaniasis -- Antimony accounted sequel post Kala-Azar dermal Leishmaniasis -- Part III Molecular featrues of drug resistant Leishmania -- Genetic Expression and drug resistance, the role of proteomics -- The role of AMC transporters in drug-resistant Leishmania -- Functional analysis of Leishmania membrane (non AMC) transporters involved in drug resistance -- Part IV Pharmacology and chemotherapy of Leishmaniasis -- Classical vs. novel treatment regimens -- Bioinformatics in Leishmania drug design -- Leishmanis mitochondria, a druggable organelle -- P-glycoprotein-like transporters in Leishmania: a search for reversal agents -- Part V Strategies to circumvent drug resistance in Leishmania -- The relevance of susceptibility tests, breakpoints and markers -- The concept of fitness in Leishmania.
330   $aDrug resistance is a fundamental factor in treatment failure in diseases like leishmaniasis, although additional factors also play a role in this phenomenon. This volume is the second edition of a well-received book that provides a comprehensive update on the pathology of the disease, as well as on the concept of parasitic drug resistance, its molecular basis, consequences and possible treatments. A valuable resource for scientists both from academia and industry involved in biomedical research and drug design, the book provides the knowledge needed to understand leishmaniasis and to contibute to combatting this disease worldwide.
606   $aDrug resistance
606   $aInfectious diseases
606   $aPharmaceutical technology
606   $aVaccines
606   $aParasitology
606   $aMicrobiology
606   $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020
606   $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096
606   $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010
606   $aVaccine$3https://scigraph.springernature.com/ontologies/product-market-codes/B16010
606   $aParasitology$3https://scigraph.springernature.com/ontologies/product-market-codes/B19002
606   $aMicrobiology$3https://scigraph.springernature.com/ontologies/product-market-codes/L23004
615  0$aDrug resistance.
615  0$aInfectious diseases.
615  0$aPharmaceutical technology.
615  0$aVaccines.
615  0$aParasitology.
615  0$aMicrobiology.
615 14$aDrug Resistance.
615 24$aInfectious Diseases.
615 24$aPharmaceutical Sciences/Technology.
615 24$aVaccine.
615 24$aParasitology.
615 24$aMicrobiology.
676   $a616.9364
702   $aPonte-Sucre$b Alicia$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aPadrón-Nieves$b Maritza$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298399603321
996   $aDrug Resistance in Leishmania Parasites$91945669
997   $aUNINA